Citigroup Raises Quest Diagnostics (NYSE:DGX) Price Target to $145.00

Quest Diagnostics (NYSE:DGX – Free Report) had its target price boosted by Citigroup from $130.00 to $145.00 in a research report report published on Monday morning, Benzinga reports. They currently have a neutral rating on the medical research company’s stock. DGX has been the subject of a number of other research reports. JPMorgan Chase & […]

Leave a Reply

Your email address will not be published.

Previous post Goldwein & Towner: Social Security can’t grow its way solvent
Next post NIKE (NYSE:NKE) Upgraded by Citigroup to “Buy”